Using Sleep Health to Optimize Smoking Cessation Treatment Response in HIV-Positive Adults

NIH RePORTER · NIH · R01 · $109,026 · view on reporter.nih.gov ↗

Abstract

Abstract Parent Grant: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in adults living with HIV (ALHIV), and cigarette smoking is the single most important modifiable CVD risk factor in this population. Success rates for existing smoking cessation interventions are relatively low. Poor sleep is more prevalent among smokers, more prevalent among ALHIV, can be caused by smoking cessation attempts, predicts relapse to former smoking patterns, and represents a parallel pathway to morbidity including increased cardiovascular disease (CVD) among ALHIV. Thus, unhealthy sleep may make smoking cessation more difficult and increase cardiovascular risk and other poor health conditions in ALHIV. Yet, poor sleep is amenable to nonpharmacologic interventions, and a pilot study from our group revealed that a sleep health intervention increased smoking cessation rates when added to routine smoking cessation treatment. To evaluate the efficacy of our sleep training approach to improve sleep health and increase smoking cessation rates in ALHIV, the proposed study will supplement an empirically-supported smoking cessation program (6- session, 15-week counseling program with varenicline) with a Sleep Training Approach to Reducing Smoking (STARS) intervention developed for smokers. STARS will be compared to a General Health (GH) educational control. The study will recruit N=200 ALHIV smokers who are interested in quitting. They will be randomized to smoking cessation with either STARS (N=100) or GH (N=100). The study will measure the efficacy of STARS versus GH to improve objectively measured healthy sleep metrics, assess its impact on smoking cessation as well as other metrics of CVD risk, and determine whether cognitive and affective variables mediate the association between sleep health and smoking cessation. Results of these studies will provide practical information as well as mechanistic insight into how sleep health can be leveraged to optimize smoking cessation treatment in ALHIV. Supplement: This diversity supplement includes research and training components. The training component will provide the candidate with the mentorship and development experiences necessary to successfully compete for a K award application. The research component will recruit intervention non-responders into a novel smoking and sleep intervention based on Acceptance and Commitment Therapy (ACT). Research aims of the supplement include (1) Determine the feasibility and acceptability of the intervention in non-responder ALHIV, and (2) Determine the preliminary efficacy of the intervention for smoking cessation rates, sleep health, and cardiovascular health. .

Key facts

NIH application ID
10618603
Project number
3R01DA051321-03S1
Recipient
UNIVERSITY OF ARIZONA
Principal Investigator
Elizabeth Connick
Activity code
R01
Funding institute
NIH
Fiscal year
2022
Award amount
$109,026
Award type
3
Project period
2020-07-01 → 2025-05-31